Ph I Trial of Cell Based Therapy for DMD

General Information

Summary This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+ allogeneic muscle progenitor cells in individuals with Duchenne muscular dystrophy (DMD)
Clinical trials phase Phase 1
Start date (estimated) 2024-12-16
End date (estimated) 2027-03-03
Clinical feature
Label Duchenne muscular dystrophy
Link http://purl.obolibrary.org/obo/DOID_11723
Description A muscular dystrophy that has_material_basis_in X-linked mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT06692426
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06692426
Other study identifiers
Name 2021LS140
Source weblink https://clinicaltrials.gov/study/NCT06692426
Regulatory body approval
Name Food and Drug Administration (FDA)
Country
United States
Public contact
Email mdstemcell@umn.edu
Public email mdstemcell@umn.edu
First name Peter
Last name Kang
Phone +1 612-624-9452
Sponsors Masonic Cancer Center, University of Minnesota
Collaborators

Cells

Recruitment

Recruitment Status Not yet recruiting
Estimated number of participants 8